Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

MSB PEER ANALYSIS

Mesoblast Ltd — metric-by-metric comparison with peers and the industry median

MSBMesoblast Ltd

🇦🇺 Australia · AU · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthDividend
MSBIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
MSB+26.3%ARDX+23.7%OLMA+183.8%WVE-9.6%ORIC+2.2%EYPT+47.7%
Year-to-Date (YTD)
MSB-25.0%ARDX-7.7%OLMA-49.5%WVE-62.5%ORIC+33.0%EYPT-23.3%
1-Year
Split-adjusted
MSB+26.3%TLX-29.8%
Year-to-Date (YTD)
MSB-25.0%TLX+50.8%

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better
MSB-11.3%ARDX-39.5%OLMA-42.9%WVE-53.7%ORIC-42.6%EYPT-102.7%Median -47.5%

Net Margin

Higher is better
MSB-115.3%ARDX-13.6%OLMA—WVE-255.7%ORIC—EYPT-3,566.6%Median -125.7%

Revenue Growth

Higher is better
MSB410.4%ARDX18.2%OLMA-100.0%WVE-31.6%ORIC-100.0%EYPT-86.4%Median 5.1%

P/E

Lower is better

ROE

Higher is better
MSB-11.3%TLX-1.8%Median -47.5%

Net Margin

Higher is better
MSB-115.3%TLX-0.9%Median -125.7%

Revenue Growth

Higher is better
MSB410.4%TLX56.3%Median 5.1%

All Metrics

Valuation
MetricMSBARDXOLMAWVEORICEYPTInd. Median
P/E——————18.06
P/B—8.902.702.50●2.765.233.62
EV/EBITDA——————15.13
P/S31.303.09●—17.79—158.3310.65
Financial Health
MetricMSBARDXOLMAWVEORICEYPTInd. Median
Current Ratio—3.4910.8811.2616.33●6.665.90
Debt/Equity—140.1%0.2%●3.1%0.8%8.8%10.9%
NetDebt/EBITDA—1.172.733.032.080.78●1.15
Profitability
MetricMSBARDXOLMAWVEORICEYPTInd. Median
Net Margin-115.3%-13.6%●—-255.7%—-3,566.6%-125.7%
ROE-11.3%●-39.5%-42.9%-53.7%-42.6%-102.7%-47.5%
ROA-8.6%●-12.7%-39.4%-42.1%-39.8%-83.5%-35.8%
EBITDA Margin-76.6%-6.0%●—-243.2%—-3,415.1%-105.8%
Growth + Dividend
MetricMSBARDXOLMAWVEORICEYPTInd. Median
Rev. Growth410.4%●18.2%-100.0%-31.6%-100.0%-86.4%5.1%
NI Growth——————12.1%
Div. Yield0.0%—————0.2%
Payout0.0%—————0.0%
Valuation
MetricMSBTLXInd. Median
P/E——18.06
P/B—6.383.62
EV/EBITDA—120.2015.13
P/S31.303.24●10.65
Financial Health
MetricMSBTLXInd. Median
Current Ratio—1.435.90
Debt/Equity—112.3%10.9%
NetDebt/EBITDA—13.131.15
Profitability
MetricMSBTLXInd. Median
Net Margin-115.3%-0.9%●-125.7%
ROE-11.3%-1.8%●-47.5%
ROA-8.6%-0.7%●-35.8%
EBITDA Margin-76.6%3.0%●-105.8%
Growth + Dividend
MetricMSBTLXInd. Median
Rev. Growth410.4%●56.3%5.1%
NI Growth——12.1%
Div. Yield0.0%—0.2%
Payout0.0%—0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on MSB

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.